“Standardization of Myocardial Protection: Comment on Cardiac Surgery 2023 Reviewed”

Thorac Cardiovasc Surg
DOI: 10.1055/a-2514-2076

Reply to Letter to the Editor

Murat Mukharyamov

¹Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany

,

Hristo Kirov

¹Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany

,

Tulio Caldonazo

¹Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany

,

Torsten Doenst

¹Department of Cardiothoracic Surgery, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany

References
1 Tevaeara Stahel H, Barandun S, Kaufmann E. et al. Single-center experience with the combination of Cardioplexol™ cardioplegia and MiECC for isolated coronary artery bypass graft procedures. J Thorac Dis 2019; 11 (Suppl. 10) S1471-S1479
2 Mukharyamov M, Schneider U, Kirov H, Caldonazo T, Doenst T. Myocardial protection in cardiac surgery-hindsight from the 2020s. Eur J Cardiothorac Surg 2023; 64 (06) ezad424
3 Veres G, Radovits T, Merkely B, Karck M, Szabó G. Custodiol-N, the novel cardioplegic solution reduces ischemia/reperfusion injury after cardiopulmonary bypass. J Cardiothorac Surg 2015; 10: 27
4 Szabó G, Brlecic P, Loganathan S. et al. Custodiol-N versus Custodiol: a prospective randomized double-blind multicentre phase III trial in patients undergoing elective coronary bypass surgery. Eur J Cardiothorac Surg 2022; 62 (05) ezac287
5 Tevaearai HT, WG, Landowski P, Carrel T, Schmidli J, Voet B, Grabenwöger M. A single-centre, single-blind, randomized, active-controlled phase 3 non-inferiority study to investigate the safety and efficacy of the cardioplegic solution Cardioplexol™. Front Cardiovasc Med 2024 ;2024 (Submitted)